Literature DB >> 6368589

Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.

H A Chapman, O L Stone, Z Vavrin.   

Abstract

Fibrin deposition is prominent in the histopathology of a number of inflammatory lung diseases. Plasmin, activated locally in the lung, can degrade not only this fibrin but potentially structural proteins important to normal lung architecture. Because alveolar macrophages are prominent in inflammatory processes of the lung, we examined the plasminogen activator (PA) activity of human alveolar macrophages. Intact alveolar macrophages from each of 10 healthy subjects expressed PA activity. There was no difference in activity between smoking and nonsmoking individuals. The activator activity was largely cell-associated, but under certain culture conditions, macrophages released a soluble activator into the culture medium. The membrane-bound activator had an apparent molecular mass of 52-55 kD in nonreduced sodium dodecyl sulfate (SDS) gels, and monospecific antibody to urokinase neutralized the enzyme activity. Immunoprecipitation of [35S]methionine-labeled cells showed that human alveolar macrophages actually synthesize the PA in vitro. SDS-gel analysis of the immunoprecipitated material revealed the predominant species of PA to be structurally similar to reduced, active urokinase. We also examined the role of PA in the degradation of both insoluble fibrin and elastin matrices by live macrophages. Cells degraded an insoluble fibrin matrix in the presence of plasminogen whether or not the macrophages contacted the fibrin as long as proteinase inhibitors were not in the culture medium. In the presence of serum proteinase inhibitors, macrophages still degraded a fibrin matrix, but only if they were in contact with the fibrin. Live macrophages also degraded insoluble elastin only when in contact with the elastin but could do so even in the presence of serum proteinase inhibitors. In matrices containing a mixture of fibrin and elastin, cells did not degrade elastin unless plasminogen was added to the medium. These results indicate that normal alveolar macrophages synthesize and express, probably at the cell surface, a PA. The PA is physically and immunochemically similar to urokinase but is membrane bound. The PA is critical to the degradation of fibrin matrices by normal alveolar macrophages. Under tissue conditions where elastin is embedded within other structural proteins, the activator may be rate-limiting in elastin degradation as well. The findings also suggest that live macrophage proteolytic activity is relatively insensitive to the presence of serum proteinase inhibitors, suggesting a mechanism for proteolytic lung injury even in the presence of proteinase-proteinase inhibitor balance in the soluble phase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368589      PMCID: PMC425084          DOI: 10.1172/JCI111275

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Modulation of plasminogen activator secretion by activated macrophages: influence of serum factors and correlation with tumoricidal potential.

Authors:  H A Chapman; Z Vavrin; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

2.  Analysis of macrophage surface receptors. I. Binding of alpha-macroglobulin . protease complexes to rabbit alveolar macrophages.

Authors:  J Kaplan; M L Nielsen
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

3.  Elastase and lysozyme activities in human alveolar macrophages. Effects of cigarette smoking.

Authors:  L M Hinman; C A Stevens; R A Matthay; J B Gee
Journal:  Am Rev Respir Dis       Date:  1980-02

Review 4.  Elastin structure, biosynthesis, and relation to disease states.

Authors:  L B Sandberg; N T Soskel; J G Leslie
Journal:  N Engl J Med       Date:  1981-03-05       Impact factor: 91.245

5.  Characterization of the metabolic responses of the human pulmonary alveolar macrophage.

Authors:  G Papermaster-Bender; M E Whitcomb; A L Sagone
Journal:  J Reticuloendothel Soc       Date:  1980-08

6.  Elastolytic activity of alveolar macrophages in normal dogs and human subjects.

Authors:  M R Green; J S Lin; L B Berman; M M Osman; J M Cerreta; I Mandl; G M Turino
Journal:  J Lab Clin Med       Date:  1979-10

7.  Plasminogen activator production by human monocytes. I. Enhancement by activated lymphocytes and lymphocyte products.

Authors:  D K Greineder; K J Connorton; J R David
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

8.  Degradation of connective tissue matrices by macrophages. III. Morphological and biochemical studies on extracellular, pericellular, and intracellular events in matrix proteolysis by macrophages in culture.

Authors:  Z Werb; D F Bainton; P A Jones
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

9.  Degradation of connective tissue matrices by macrophages. II. Influence of matrix composition on proteolysis of glycoproteins, elastin, and collagen by macrophages in culture.

Authors:  P A Jones; Z Werb
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

10.  Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages.

Authors:  Z Werb; M J Banda; P A Jones
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  33 in total

1.  Secretion of plasminogen activator inhibitor by normal rat pleural leukocytes in culture.

Authors:  X Y Li; G M Brown; D Lamb; K Donaldson
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3.

Authors:  Xian Wu Cheng; Masafumi Kuzuya; Kae Nakamura; Qun Di; Zexuan Liu; Takeshi Sasaki; Shigeru Kanda; Hai Jin; Guo-Ping Shi; Toyoaki Murohara; Mitsuhiro Yokota; Akihisa Iguchi
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development.

Authors:  H G Welgus; E J Campbell; J D Cury; A Z Eisen; R M Senior; S M Wilhelm; G I Goldberg
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.

Authors:  H A Chapman; O L Stone
Journal:  Biochem J       Date:  1985-08-15       Impact factor: 3.857

6.  Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface.

Authors:  K A Hajjar; R L Nachman
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes.

Authors:  R G Sitrin; R F Todd; E Albrecht; M R Gyetko
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

8.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

9.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.

Authors:  A R Nusrat; H A Chapman
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.